Back

Purple Biotech shares surge 22.89% after U.S. patent allowance

Verifying
  • Purple Biotech received a USPTO Notice of Allowance for a tri-specific antibody patent application.
  • 22.89%: Purple Biotech shares reached $2.03 in Wednesday premarket trading.
  • Purple Biotech aims to begin human trials of IM1240 in 2027.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.